Cargando…
Circulating Long Noncoding RNAs Act as Diagnostic Biomarkers in Non-Small Cell Lung Cancer
Identification of novel effective early diagnostic biomarkers may provide alternative strategies to reduce the mortality for non-small cell lung cancer (NSCLC) patients. Circulating long non-coding RNAs (lncRNAs) have emerged as a new class of promising cancer biomarkers. Our study aimed to identify...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7793881/ https://www.ncbi.nlm.nih.gov/pubmed/33425713 http://dx.doi.org/10.3389/fonc.2020.537120 |
_version_ | 1783634088627798016 |
---|---|
author | Yuan, Shuai Xiang, Ying Guo, Xiaoping Zhang, Yao Li, Chengying Xie, Weijia Wu, Na Wu, Long Cai, Tongjian Ma, Xiangyu Yu, Zubin Bai, Li Li, Yafei |
author_facet | Yuan, Shuai Xiang, Ying Guo, Xiaoping Zhang, Yao Li, Chengying Xie, Weijia Wu, Na Wu, Long Cai, Tongjian Ma, Xiangyu Yu, Zubin Bai, Li Li, Yafei |
author_sort | Yuan, Shuai |
collection | PubMed |
description | Identification of novel effective early diagnostic biomarkers may provide alternative strategies to reduce the mortality for non-small cell lung cancer (NSCLC) patients. Circulating long non-coding RNAs (lncRNAs) have emerged as a new class of promising cancer biomarkers. Our study aimed to identify circulating lncRNAs for diagnosing NSCLC. A total 528 plasma samples were continuously collected and allocated to four progressive phases: discovery, training, verification, and expansion phases. The expression of candidate lung cancer related lncRNAs were detected using quantitative reverse-transcriptase polymerase chain reaction (qRT-PCR). We identified a 4-lncRNA panel (RMRP, NEAT1, TUG1, and MALAT1) that provided a high diagnostic value in NSCLC (AUC = 0.86 and 0.89 for training and verification phase, respectively). Subgroup analyses showed that the 4-lncRNA panel had a sensitivity of 78.95% [95% confidence interval (CI) = 62.22%–89.86%] in stage I-II patients and 75.00% (95% CI = 52.95%–89.40%) in patients with small tumor size (≤3cm). Notably, the sensitivity of 4-lncRNA panel was significantly higher than that of routine protein panels in adenocarcinoma (CEA, CA125, and CYFRA21-1, 86.30% vs. 73.96%). Adding 4-lncRNA to protein markers significantly improved the diagnostic capacity in both adenocarcinoma (AUC=0.85, 95% CI = 0.78–0.91) and squamous cell carcinoma (AUC=0.93, 95% CI = 0.86–0.97). In conclusion, we identified a plasma 4-lncRNA panel that has considerable clinical value in diagnosing NSCLC. The 4-lncRNA panel could improve the diagnostic values of routine tumor protein markers in diagnosing NSCLC. Circulating lncRNAs could be used as promising candidates for NSCLC diagnosis. |
format | Online Article Text |
id | pubmed-7793881 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-77938812021-01-09 Circulating Long Noncoding RNAs Act as Diagnostic Biomarkers in Non-Small Cell Lung Cancer Yuan, Shuai Xiang, Ying Guo, Xiaoping Zhang, Yao Li, Chengying Xie, Weijia Wu, Na Wu, Long Cai, Tongjian Ma, Xiangyu Yu, Zubin Bai, Li Li, Yafei Front Oncol Oncology Identification of novel effective early diagnostic biomarkers may provide alternative strategies to reduce the mortality for non-small cell lung cancer (NSCLC) patients. Circulating long non-coding RNAs (lncRNAs) have emerged as a new class of promising cancer biomarkers. Our study aimed to identify circulating lncRNAs for diagnosing NSCLC. A total 528 plasma samples were continuously collected and allocated to four progressive phases: discovery, training, verification, and expansion phases. The expression of candidate lung cancer related lncRNAs were detected using quantitative reverse-transcriptase polymerase chain reaction (qRT-PCR). We identified a 4-lncRNA panel (RMRP, NEAT1, TUG1, and MALAT1) that provided a high diagnostic value in NSCLC (AUC = 0.86 and 0.89 for training and verification phase, respectively). Subgroup analyses showed that the 4-lncRNA panel had a sensitivity of 78.95% [95% confidence interval (CI) = 62.22%–89.86%] in stage I-II patients and 75.00% (95% CI = 52.95%–89.40%) in patients with small tumor size (≤3cm). Notably, the sensitivity of 4-lncRNA panel was significantly higher than that of routine protein panels in adenocarcinoma (CEA, CA125, and CYFRA21-1, 86.30% vs. 73.96%). Adding 4-lncRNA to protein markers significantly improved the diagnostic capacity in both adenocarcinoma (AUC=0.85, 95% CI = 0.78–0.91) and squamous cell carcinoma (AUC=0.93, 95% CI = 0.86–0.97). In conclusion, we identified a plasma 4-lncRNA panel that has considerable clinical value in diagnosing NSCLC. The 4-lncRNA panel could improve the diagnostic values of routine tumor protein markers in diagnosing NSCLC. Circulating lncRNAs could be used as promising candidates for NSCLC diagnosis. Frontiers Media S.A. 2020-12-07 /pmc/articles/PMC7793881/ /pubmed/33425713 http://dx.doi.org/10.3389/fonc.2020.537120 Text en Copyright © 2020 Yuan, Xiang, Guo, Zhang, Li, Xie, Wu, Wu, Cai, Ma, Yu, Bai and Li http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Yuan, Shuai Xiang, Ying Guo, Xiaoping Zhang, Yao Li, Chengying Xie, Weijia Wu, Na Wu, Long Cai, Tongjian Ma, Xiangyu Yu, Zubin Bai, Li Li, Yafei Circulating Long Noncoding RNAs Act as Diagnostic Biomarkers in Non-Small Cell Lung Cancer |
title | Circulating Long Noncoding RNAs Act as Diagnostic Biomarkers in Non-Small Cell Lung Cancer |
title_full | Circulating Long Noncoding RNAs Act as Diagnostic Biomarkers in Non-Small Cell Lung Cancer |
title_fullStr | Circulating Long Noncoding RNAs Act as Diagnostic Biomarkers in Non-Small Cell Lung Cancer |
title_full_unstemmed | Circulating Long Noncoding RNAs Act as Diagnostic Biomarkers in Non-Small Cell Lung Cancer |
title_short | Circulating Long Noncoding RNAs Act as Diagnostic Biomarkers in Non-Small Cell Lung Cancer |
title_sort | circulating long noncoding rnas act as diagnostic biomarkers in non-small cell lung cancer |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7793881/ https://www.ncbi.nlm.nih.gov/pubmed/33425713 http://dx.doi.org/10.3389/fonc.2020.537120 |
work_keys_str_mv | AT yuanshuai circulatinglongnoncodingrnasactasdiagnosticbiomarkersinnonsmallcelllungcancer AT xiangying circulatinglongnoncodingrnasactasdiagnosticbiomarkersinnonsmallcelllungcancer AT guoxiaoping circulatinglongnoncodingrnasactasdiagnosticbiomarkersinnonsmallcelllungcancer AT zhangyao circulatinglongnoncodingrnasactasdiagnosticbiomarkersinnonsmallcelllungcancer AT lichengying circulatinglongnoncodingrnasactasdiagnosticbiomarkersinnonsmallcelllungcancer AT xieweijia circulatinglongnoncodingrnasactasdiagnosticbiomarkersinnonsmallcelllungcancer AT wuna circulatinglongnoncodingrnasactasdiagnosticbiomarkersinnonsmallcelllungcancer AT wulong circulatinglongnoncodingrnasactasdiagnosticbiomarkersinnonsmallcelllungcancer AT caitongjian circulatinglongnoncodingrnasactasdiagnosticbiomarkersinnonsmallcelllungcancer AT maxiangyu circulatinglongnoncodingrnasactasdiagnosticbiomarkersinnonsmallcelllungcancer AT yuzubin circulatinglongnoncodingrnasactasdiagnosticbiomarkersinnonsmallcelllungcancer AT baili circulatinglongnoncodingrnasactasdiagnosticbiomarkersinnonsmallcelllungcancer AT liyafei circulatinglongnoncodingrnasactasdiagnosticbiomarkersinnonsmallcelllungcancer |